Genascence Announces U.S. Food and Drug Administration Grants Regenerative Medicine Advanced Therapy Designation to GNSC-001 for Knee Osteoarthritis (OA)
UF startup Genascence Corporation announced that the U.S. FDA has granted Regenerative Medicine Advanced Therapy (RMAT) designation to GNSC-001, a potential first-in-class gene therapy that targets interleukin-1 (IL-1) for the treatment of knee osteoarthritis (OA)